X4 Pharmaceuticals reports Q4 EPS (20c) vs. (10c) last year

Reports Q4 revenue $1.4M vs. $0 last year. “As expected, 2024 was a transformative year for the company and our momentum has continued into 2025,” said Paula Ragan, Ph.D., President and CEO of X4 Pharmaceuticals (XFOR). “With the U.S. approval and launch of our first product, XOLREMDI in WHIM syndrome, we are now a fully integrated company advancing our mission to serve those with rare immunodeficiencies and few treatment options. As we await word from the EU regulatory authority on the potential approval of mavorixafor for WHIM in that region, we’ve continued to expand our potential reach to the global WHIM community through our recently completed commercialization partnerships in the EU, Australia, New Zealand, and the Middle East and North Africa territories.”